Cipla Ltd Share Price
(CIPLA)
₹1541.5
as on 04:01PM, 29 Apr 2025
Cipla Performance
Day's Low
Day's High
₹1,531Day's Price Range₹1,560.652 Week's Low
52 Week's High
₹1,317.2552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | + 6.73 % |
| 3 Month Return | + 5.77 % |
| 1 Year Return | + 10.11 % |
| Market Stats | |
| Previous Close | ₹1,555.10 |
| Open | ₹1,555.00 |
| Volume | 13.85L |
| Upper Circuit | ₹1,710.60 |
| Lower Circuit | ₹1,399.60 |
| Market Cap | ₹1,24,497.77Cr |
Cipla Fundamentals
P/E Ratio
24.95
PEG Ratio
1.57
Market Cap
₹1,24,497.77 Cr
P/B Ratio
4.31
EPS
51.47
Dividend Yield
0.87
Sector
Pharmaceuticals
ROE
15.5
Mutual Fund Holdings of Cipla
Cipla Analyst Rating
based on 37 analysts
64.86%
Buy
21.62%
Hold
13.51%
Sell
Based on 37 analysts offering long term price targets for Cipla. An average target of ₹1640.92
Source: S&P Global Market Intelligence
Cipla Share analysis
Cipla price forecast by 37 analysts
Upside of6.45%
High
₹1875
Target
₹1640.92
Low
₹1204
Cipla target price ₹1640.92, a slight upside of 6.45% compared to current price of ₹1541.5. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:24.62%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:30.42%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Cipla Ltd
Cipla Plans US Expansion with Strong Pipeline - 27 Apr, 2025
Cipla aims to enhance its US presence through manufacturing expansion and strategic partnerships. The company has a robust pipeline, including key respiratory drug filings, and significant revenue contributions from the US market.Cipla Expands Services and Reports Strong Earnings - 21 Apr, 2025
Cipla's Goa facility received a VAI classification from the US FDA, while the company reported a significant profit increase in Q3 FY25. Additionally, Cipla Foundation expanded palliative care services in Pune, aiding over 900 cancer patients.Cipla's Medispray Facility Receives VAI Classification - 18 Apr, 2025
Cipla Ltd announced that its Medispray Laboratories facility in Goa received a Voluntary Action Indicated (VAI) classification from the USFDA, indicating non-critical issues. The company views this as part of its commitment to good governance practices.Nomura Reaffirms Buy Rating on Cipla with Target Price - 14 Apr, 2025
Nomura maintains a 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. The approval of gAbraxane by the USFDA enhances Cipla's market visibility, with expected revenues of $18 million and $56 million for FY26 and FY27, respectively. Despite competition, Cipla is anticipated to capture significant market share.Cipla Secures USFDA Approval for Generic Cancer Drug - 11 Apr, 2025
Cipla Limited received final USFDA approval for its generic version of Abraxane, enhancing its oncology portfolio. The product is expected to launch in the first half of FY 2025-26, leading to a 5% share price increase.Cipla Secures FDA Approval and Announces Earnings Date - 10 Apr, 2025
Cipla has received USFDA approval for Lanreotide injection, marking a significant milestone for its US business. Additionally, the company announced its Q4 FY2025 earnings release date and potential dividend on May 13, 2025.Cipla Reports Strong Q3 FY25 Financial Results - 08 Apr, 2025
Cipla Ltd announced a revenue of Rs 7,073 crore and a net profit of Rs 1,575 crore for Q3 FY25, reflecting significant growth compared to the previous year.Cipla Faces Pressure Amid Pharma Index Decline - 07 Apr, 2025
Cipla's stock faced downward pressure as its share price contributed to the NSE Nifty Pharma index reaching its lowest level in over 10 months.Cipla Shares Plummet Amid Tariff Concerns - 04 Apr, 2025
Cipla Ltd's shares fell 6.08% due to concerns over potential U.S. pharmaceutical tariffs announced by President Trump, impacting investor sentiment significantly.Cipla Shares Surge After U.S. Tariff Exemption - 03 Apr, 2025
Cipla's stock gained significantly after the U.S. government exempted pharmaceuticals from new tariffs, providing relief to Indian generic drug exporters. The broader Nifty Pharma index also rallied, reflecting positive market sentiment.Concerns Over US Tariffs Impacting Indian Pharma - 30 Mar, 2025
India's pharma sector faces challenges due to a 10% tariff on US imports, raising concerns among industry groups about the financial burden on distributors and generic manufacturers.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 4 quarters, 939.04 Cr → 1.57K Cr (in ₹), with an average increase of 15.6% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 20.42% to 20.47% in Mar 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, CIPLA stock has moved up by 1.8%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 6.41K Cr → 7.29K Cr (in ₹), with an average increase of 4.2% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 78.5%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 40.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 29.13% of holdings in Mar 2025 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 16.41% to 16.33% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 26.60% to 26.22% in Mar 2025 quarter
Cipla Financials
Cipla Index Inclusions
Cipla Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | 0.00 | |
| Foreign Institutions | 26.22% | 0.00 | |
| Mutual Funds | 20.47% | 0.00 | |
| Retail Investors | 16.33% | 0.00 | |
| Others | 7.85% | 0.00 |
Cipla Key Indicators
Cipla Valuation
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (24.95x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (42.80x)
January 23, 2018
Cipla Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 48.74% since last year same period to ₹1,570.51Cr in the Q3 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 20.57% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.39%.
Read More about Dividends
Cipla Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bullish trading position according to technical analysis indicators.
Cipla Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,24,497.77 Cr | 32.29% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,62,148.21 Cr | 32.36% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,12,450.22 Cr | 36.67% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,281.13 Cr | -1.98% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,278.43 Cr | -4.47% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Revenue: ₹6,961.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,583.72Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Cipla Ltd
What is Cipla Ltd price today?
Cipla Ltd share price today stands at ₹1541.5, Open: ₹1555, Previous Close: ₹1555.1, High: ₹1560.6, Low: ₹1531, 52 Week High: ₹1702.05, 52 Week Low: ₹1317.25.
How to Buy Cipla Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Cipla Ltd shares
What are today's traded volumes of Cipla Ltd?
Today's traded volume of Cipla Ltd(CIPLA) is 13.85L.
What is today's market capitalisation of Cipla Ltd?
Today's market capitalisation of Cipla Ltd(CIPLA) is ₹124497.77Cr.
What is the 52 Week High and Low Range of Cipla Ltd?
How much percentage Cipla Ltd is down from its 52 Week High?
Cipla Ltd (CIPLA) share price is ₹1541.5. It is down -9.43% from its 52 Week High price of ₹1702.05
How much percentage Cipla Ltd is up from its 52 Week low?
Cipla Ltd (CIPLA) share price is ₹1541.5. It is up 17.02% from its 52 Week Low price of ₹1317.25